Why is ALBLU.PA stock falling pre-market?

ALBLU.PA stock is pressured by weak earnings (EPS **-0.06**), a low current ratio (**0.46**), and high debt-to-equity (**7.48**). These fundamentals, plus low liquidity and underperformance versus sector peers, drive selling ahead of the open.

What is Meyka AI's forecast for ALBLU.PA stock?

Meyka AI's forecast model projects a quarterly price of **€0.40** and a monthly price of **€0.35**. Compared with the current **€0.48**, the model implies near-term downside of **-17.01%** to **-27.38%**. Forecasts are model-based projections and not guarantees.

What are realistic price targets for ALBLU.PA stock?

We give a bear target **€0.25**, base **€0.40**, and bull **€0.75** on EURONEXT. The base aligns with Meyka AI's quarterly forecast and reflects weak margins and leverage versus Healthcare peers.

How does Bluelinea (ALBLU.PA) compare to its sector?

ALBLU.PA shows weaker liquidity and profitability than the Healthcare sector, which typically posts higher PE and PB ratios. Bluelinea's margin and leverage metrics place it below sector averages and increase relative risk.

EU Stocks

ALBLU.PA down 51% YTD on EURONEXT pre-market: assess near-term risks

ByDanny Kontos January 7, 2026January 7, 2026

ALBLU.PA stock opens pre-market on EURONEXT at €0.48, down 51.00% YTD and ranking among the session’s top losers. Trading volume is light at 2,344 shares versus a 50-day average of 3,965. Investors face weak profitability with EPS -0.06 and PE -8.58, and a small market cap of €9,438,476.00. This note explains drivers behind the drop, highlights key ratios, and flags near-term price targets for Europe-listed Bluelinea SA (ALBLU.PA)